No elevated genomic damage in children and adolescents with attention deficit/hyperactivity disorder after methylphenidate therapy.

@article{Walitza2009NoEG,
  title={No elevated genomic damage in children and adolescents with attention deficit/hyperactivity disorder after methylphenidate therapy.},
  author={Susanne Walitza and Kristina K{\"a}mpf and Natalia Artamonov and Marcel Romanos and Rajaraman Gnana Oli and Susanne Wirth and Andreas Warnke and Manfred Gerlach and Helga Stopper},
  journal={Toxicology letters},
  year={2009},
  volume={184 1},
  pages={
          38-43
        }
}
BACKGROUND AND OBJECTIVE Attention-deficit/hyperactivity disorder (ADHD) is the most frequent psychiatric disorder in children and adolescents and is often treated with methylphenidate (MPH), resulting in MPH exposure in more than 1% of all children in many countries. A 2005 report on cytogenetic effects in peripheral lymphocytes from 12 ADHD children treated for 3 months with MPH raised questions about its genetic toxicity and potential carcinogenicity. In 2007, we described no elevated… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 10 CITATIONS

Similar Papers

Loading similar papers…